Reducing neonatal morbidity by discontinuing oxytocin during the active phase of first stage of labor: a multicenter randomized controlled trial STOPOXY.

ABSTRACT: BACKGROUND:Oxytocin is effective in reducing labor duration, but can be associated with fetal and maternal complications such as neonatal acidosis and post-partum hemorrhage. When comparing discontinuing oxytocin in the active phase with continuing oxytocin infusion, previous studies were underpowered to show a reduction in neonatal morbidity. Thus, we aim at evaluating the impact of discontinuing oxytocin during the active phase of the first stage of labor on the neonatal morbidity rate. METHODS:STOPOXY is a multicenter, randomized, open-label, controlled trial conducted in 20 maternity units in France. The first participant was recruited January 17th 2020. The trial includes women with a live term (?37?weeks) singleton, in cephalic presentation, receiving oxytocin before 4?cm, after an induced or spontaneous labor. Women aged ?10?mmol/L and/or umbilical arterial lactates>?7?mmol/L and/or a 5?min Apgar score?

SUBMITTER: Girault A 

PROVIDER: S-EPMC7576841 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature